Company gained license to HZI’s hydrocyclone technology.
Sartorius Biotech signed an agreement to use Helmholtz Centre for Infection Research’s (HZI) hydrocyclone technology. Sartorius thus secured exclusive rights to the development, production, and sale of products utilizing this technology.
Hydrocyclones are efficient and robust perfusion systems for continuous cell culturing processes, which Sartorius says it will offer as disposable products for conventional bioreactor systems and single-use bioreactors. The easy scalability, a reduced outlay for equipment, simple handling, and short cell dwell-times make these systems suited for the development and production of biopharmaceutical proteins, according to the company.
When fresh culture medium is added during target protein harvesting, the hydrocyclone briefly exerts minimal hydrodynamic shearing forces on the cells. In contrast to classic batch or fed-batch processes that do not involve the continuous exchange of medium, a hydrocyclone creates a stable vortex in the reactor vessel through the tangential inflow of culture medium. The velocity thereby generated results in highly efficient centrifugal cell separation. As a consequence of this principle, users achieve high cell densities and high volumetric production rates, Sartorius explains.
“This innovative method of hydrodynamic cell separation allows us to expand our technology and product portfolio in the cell cultivation sector,” comments Reinhard Vogt, managing director of Sartorius.
